Skip to main content
Premium Trial:

Request an Annual Quote

Epoch Said Strong Q2 Sales, Lower R&D Helped Keep Net Loss Static

NEW YORK, July 30 - Epoch Biosciences today said strong second-quarter  product sales helped drive total revenue, while a slight decrease in R&D spending helped keep net loss unchanged.


For the three-month period ended June 30, Epoch said total revenue climbed to $2.5 million from $1.8 million on year ago. Product sales, which grew to $1.7 million from $1.1 million in the year-ago period, led the growth followed by a modest growth in licensing fees and royalties, the firm said.


R&D spending in the current second quarter, meanwhile, fell to $1.1 million from $1.2 million year over year, according to Epoch. Spending on sales and marketing, however, increased to $319,000 in the second quarter 2002 from $106,000 in the same period one year ago.


As a result, Epoch said second-quarter net loss was virtually unchanged year over year at $1.2 million, or $.05 per share.


The company said it had roughly $5 million in cash and cash equivalents as of June 30. It had about $8.4 during the same period one year ago.


Click here for more information.

The Scan

Genes Linked to White-Tailed Jackrabbits' Winter Coat Color Change

Climate change, the researchers noted in Science, may lead to camouflage mismatch and increase predation of white-tailed jackrabbits.

Adenine Base Editor Targets SCID Mutation in New Study

Researchers from the University of California, Los Angeles, report in Cell that adenine base editing was able to produce functional T lymphocytes in a model of severe combined immune deficiency.

Researchers Find Gene Affecting Alkaline Sensitivity in Plants

Researchers from the Chinese Academy of Science have found a locus affecting alkaline-salinity sensitivity, which could aid in efforts to improve crop productivity, as they report in Science.

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.